COLL vs KLAC · P/E 17, rev $181.9M vs P/E 55, rev $12.16B
Collegium Pharmaceutical Inc (COLL) versus KLA Corporation (KLAC) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
KLA Corporation (KLAC) is a semiconductor equipment & materials company listed on US.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported KLAC revenue for 2025-06-30 was $12.16B. Net income was $4.06B. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. KLAC currently screens at market cap $252.01B and trailing P/E 54.7.
Not investment advice. Open the COLL and KLAC stock pages for the full models.
Not investment advice.